Gainers

  • HCW Biologics (NASDAQ:HCWB) stock increased by 126.4% to $2.4 during Wednesday's regular session. The market value of their outstanding shares is at $7.1 million. As per the news, the Q1 earnings report came out 4 days ago.
  • Silexion Therapeutics (NASDAQ:SLXN) stock rose 77.58% to $0.48. The market value of their outstanding shares is at $1.0 million. The company's, Q1 earnings came out 3 days ago.
  • MetaVia (NASDAQ:MTVA) stock increased by 54.78% to $2.91. The market value of their outstanding shares is at $9.7 million. As per the press release, Q1 earnings came out 4 days ago.
  • BiomX (AMEX:PHGE) stock moved upwards by 36.71% to $0.51. The market value of their outstanding shares is at $3.7 million.
  • Immunovant (NASDAQ:IMVT) shares increased by 36.2% to $35.81. The market value of their outstanding shares is at $5.3 billion. As per the press release, Q4 earnings came out today.
  • Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 31.26% to $3.31. The company's market cap stands at $31.5 million.

Losers

  • Wellgistics Health (NASDAQ:WGRX) shares decreased by 28.6% to $0.12 during Wednesday's regular session. The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out yesterday.
  • Sunshine Biopharma (NASDAQ:SBFM) stock decreased by 17.96% to $0.36. The market value of their outstanding shares is at $2.2 million.
  • GlucoTrack (NASDAQ:GCTK) stock declined by 16.39% to $0.46. The company's market cap stands at $2.0 million. As per the press release, Q1 earnings came out 4 days ago.
  • Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) shares declined by 15.0% to $0.09.
  • Lakewood-Amedex (NASDAQ:LABT) shares fell 14.61% to $0.74. The company's market cap stands at $12.4 million.
  • Purple Biotech (NASDAQ:PPBT) stock declined by 12.83% to $3.06. The market value of their outstanding shares is at $3.2 million. As per the news, the Q1 earnings report came out 3 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.